PH
PRVA
HealthcarePrivia Health Group, Inc.
Price Chart
Loading...
Market Data
Revenue TTMXBRL
—
Net IncomeXBRL
—
Gross MarginXBRL
—
EPS (Diluted)XBRL
—
No analysis generated yet. Run the pipeline for this company.
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
6
GuidanceBullishPer-CompanyMar 30, 2026
Privia Health Issues FY26 Revenue Guidance of $2.35B–$2.45B; Analysts Adjust Price Targets
- ▸FY26 GAAP revenue guidance $2.35B–$2.45B
- ▸Colorectal cancer screening program achieved 84% screening rate in 2024
- ▸Screening program scaled to over 100,000 patients nationally
- ▸JPMorgan raised price target to $35; Jefferies raised to $32
- ▸Citi trimmed price target to $32 citing valuation concerns